Jacek Białkowski

Jacek Białkowski

Auto-generated profile, based on publicly available information

Jacek Białkowski

Department of Pediatric Cardiology and Congenital Heart Defects, Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Open access
PDF file
KMKarol Miszalski-Jamka
Karol Miszalski-Jamka
JJJohn L. Jefferies
John L. Jefferies
WMWojciech Mazur
Wojciech Mazur
JGJan Głowacki
Jan Głowacki
JHJianhong Hu
Jianhong Hu
MBMatthew N. Bainbridge
Matthew N. Bainbridge
Background—: Left ventricular noncompaction (LVNC) is a genetically and phenotypically heterogeneous disease and, although increasingly recognized in clinical practice, there is a lack of widely accepted diagnostic criteria. We sought to identify novel genetic causes of LVNC and describe genotype–phenotype correlations. Methods and Results—: A total of 190 patients from 174 families with left ventricular hypertrabeculation (LVHT) or LVNC were referred for cardiac magnetic resonance and whole-exome sequencing. A total of 425 control individuals were included to identify variants of interest (VOIs). We found an excess of 138 VOIs in 102 (59%) unrelated patients in 54 previously identified LVNC or other known cardiomyopathy genes. VOIs were found in 68 of 90 probands with LVNC and 34 of 84 probands with LVHT (76% and 40%, respectively; P <0.001). We identified 0, 1, and ≥2 VOIs in 72, 74, and 28 probands, respectively. We found increasing number of VOIs in a patient strongly correlated with several markers of disease severity, including ratio of noncompacted to compacted myocardium ( P <0.001) and left ventricular ejection fraction ( P =0.01). The presence of sarcomeric gene mutations was associated with increased occurrence of late gadolinium enhancement ( P =0.004). Conclusions—: LVHT and LVNC likely represent a continuum of genotypic disease with differences in severity and variable phenotype explained, in part, by the number of VOIs and whether mutations are present in sarcomeric or nonsarcomeric genes. Presence of VOIs is common in patients with LVHT. Our findings expand the current clinical and genetic diagnostic approaches for patients with LVHT and LVNC.

1 February 2009 in The American Journal of Cardiology
Verified
Journal Article
Closed access
NMNicolas Majunke
Nicolas Majunke
JBJacek Bialkowski
Jacek Bialkowski
NWNeil Wilson
Neil Wilson
MSMalgorzata Szkutnik
Malgorzata Szkutnik
JKJacek Kusa
Jacek Kusa
HSHorst Sievert
Horst Sievert

31 January 2006 in Heart
Verified
Journal Article
Open access
PDF file
MWM A Walsh
M A Walsh
JBJ Bialkowski
J Bialkowski
MSM Szkutnik
M Szkutnik
MPM Pawelec-Wojtalik
M Pawelec-Wojtalik
WBWaldemar Bobkowski
Waldemar Bobkowski
KWK P Walsh
K P Walsh
Objective: To look at the presentation, treatment and outcome of patients who developed atrioventricular block after transcatheter closure of a perimembranous ventricular septal defect (PMVSD) with the Amplatzer PMVSD device. Setting: Three tertiary referral centres for paediatric cardiology in two countries. Results: All three patients presented within 10 days of the procedure. All three patients were treated with intravenous steroids. A permanent pacemaker was inserted in all patients but no pacemaker required activation after two months. Conclusion: Complete atrioventricular block occurring in the weeks after device occlusion of a PMVSD appears to resolve quickly. Continued involvement in multicentre device databases is required to monitor safety.

1 March 2007 in Heart
Verified
Journal Article
Closed access
MSM Szkutnik
M Szkutnik
SQS A Qureshi
S A Qureshi
JKJ Kusa
J Kusa
ERE Rosenthal
E Rosenthal
JBJ Bialkowski
J Bialkowski
Transcatheter closure of a perimembranous ventricular septal defect (PmVSD) is usually performed with an asymmetric Amplatzer occluder, which is not an ideal device. Experience with the use of the Amplatzer muscular ventricular septal defect occluder (MVSO) to close selected PmVSDs is presented. Two tertiary referral centres for paediatric cardiology in two countries. To look at the safety and efficacy of the application of the MVSO in patients with appropriate PmVSD anatomy. The procedure was performed in 10 patients aged 3.2-40 (mean 12.5) years. All had a PmVSD with a mean diameter of 5.4 (range 4-11) mm, with an extension towards the muscular septum. The mean distance of the defect from the aortic valve was 5.4 (range 4-6) mm. In all but one patient, the MVSO was introduced in routine antegrade transvenous fashion (4-mm device in one patient, 6-mm device in five, 8 mm in two, 10 mm in one, and 12 mm in one). In one patient, the device was deployed by retrograde implantation. All procedures except one were performed without complications, and complete closure of the VSD was achieved. One patient with a residual shunt developed haemolysis, which resolved over 10 days. In three patients, trivial, non-progressive tricuspid regurgitation appeared after the procedure. No other complications were observed over 1.7 (range 0.2-3.5) years of follow-up. Application of the MVSO for closure of selected PmVSDs seems to be a safe and effective treatment option.

23 January 2004 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MSMalgorzata Szkutnik
Malgorzata Szkutnik
JMJozef Masura
Jozef Masura
JBJacek Bialkowski
Jacek Bialkowski
PGPavol Gavora
Pavol Gavora
PBPawel Banaszak
Pawel Banaszak
MZMarian Zembala
Marian Zembala

1 July 2005 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JBJacek Bialkowski
Jacek Bialkowski
CZCarlos Zabal
Carlos Zabal
MSMalgorzata Szkutnik
Malgorzata Szkutnik
JMJose Antonio Garcia Montes
Jose Antonio Garcia Montes
JKJacek Kusa
Jacek Kusa
MZMarian Zembala
Marian Zembala